Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) - Drugs in Development, 2021

Published	Pages	Publisher	Report code
Mar 2021	46	Global Markets Direct	ASDR-577309

Published: Mar 2021 - Pages : 46 - Publisher : Global Markets Direct - Report code : ASDR-577309

Incyte Corp
Inflection Biosciences Ltd
NewBay Medical Technology Co Ltd
Novartis AG
Onconova Therapeutics Inc
Shengke Pharmaceuticals (Jiangsu) Ltd
Sumitomo Dainippon Pharma Oncology
Inc
X-37 LLC
Yakult Honsha Co Ltd

Serine/Threonine Protein Kinase Pim 3 - Pipeline Review, H2 2020

This report can be of interest as well:

Serine/Threonine Protein Kinase Pim 3 - Pipeline Review, H2 2020

Published: July, 2020 | Report code: ASDR-559179